Breast cancer

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Retrieved on: 
Sunday, April 7, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, SOC, Melanoma Research, Oncogene, RNA-binding protein, Patient, SVP, Neoplasm, RNA, Cancer, Messenger, Melanoma, Lung cancer, Society, IND, Immortalised cell line, AACR, Breast cancer, RBP, Therapy, Translational medicine, Vaccine

These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .

Key Points: 
  • These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
  • eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
  • Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
  • “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.

MOLLI Surgical Unveils OncoPen, a New Surgical Tool for Empowering Precision and Confidence in the Operating Room

Retrieved on: 
Tuesday, April 9, 2024
Prevalence, Patient, Cancer, Surgeon, Neoplasm, Breast cancer, Surgical oncology, Health, Birth control

DEERFIELD, Ill., April 9, 2024 /PRNewswire/ -- MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer. The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System, offering sophisticated tools for precisely targeting and removing cancerous lesions.

Key Points: 
  • The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System , offering sophisticated tools for precisely targeting and removing cancerous lesions.
  • Unlike traditional techniques, it eliminates the need for wires, providing increased scheduling flexibility for surgeons and a better patient experience.
  • During surgery, the surgeon is directed using real-time 3D guidance on the MOLLI® Tablet to the precise location of the lesion.
  • "At MOLLI Surgical, our relentless focus is on the patient, placing their well-being at the core of all our efforts," said Ananth Ravi, President and CEO of MOLLI Surgical.

OOFOS Surpasses $4 Million Milestone in Project Pink Donations

Retrieved on: 
Tuesday, April 9, 2024
Ali, Breast cancer, Dana–Farber Cancer Institute, Patient, Research, Pink, Boston Marathon, The Jimmy Fund, Shoe, Woman, Microsoft Kin, MPH, PMC, Division, Nursing, Christine St-Pierre, Pharmaceutical industry

BRAINTREE, Mass., April 9, 2024 /PRNewswire/ -- OOFOS, the global leader in Active Recovery footwear, today proudly announces a monumental achievement in their Project Pink initiative, surpassing the extraordinary milestone of $4 million in all-time donations to Dana-Farber Cancer Institute and the Jimmy Fund. Through several fundraising initiatives, OOFOS solidifies its unwavering dedication to breast cancer awareness, research, and patient support.

Key Points: 
  • Since its inception in 2015, Project Pink has been a beacon of support for those battling breast cancer.
  • Since its inception in 2015, Project Pink has been a beacon of support for those battling breast cancer.
  • Through Project Pink, OOFOS donates a portion of all sales made on OOFOS.com to Dana-Farber, ultimately leading to the $4 million.
  • In addition to ongoing contributions through Project Pink, OOFOS has undertaken various impactful campaigns to further contribute to this vital cause.

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
PI3K, AADI, Fulvestrant, Patient, AACR, Cancer, Breast cancer, HR, LOS, Everolimus, Pharmaceutical industry

LOS ANGELES, April 9, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024.

Key Points: 
  • Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial
    LOS ANGELES, April 9, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance.
  • These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024.
  • Poster presentation details and abstract highlights include:
    Fulvestrant, the selective estrogen receptor degrader and PI3K inhibitors, such as alpelisib, have demonstrated efficacy in patients with HR+ PI3K-mutated breast cancer; however, resistance still occurs
    These data further support the combination of nab-sirolimus with endocrine therapy for hormone-driven cancers, as is currently being investigated in patients with advanced or recurrent endometrioid endometrial cancer in a Phase 2 study (NCT05997017)
    Corresponding with greater antitumor activity, nab-sirolimus was associated with higher intratumoral drug concentration and stronger mTOR target suppression than everolimus when the agents were combined with KRAS G12C inhibitors

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Istanbul University, Marmara University, Tekirdağ Namık Kemal University, Research, Mammography, Cancer, AI, Woman, MMG, Breast cancer, Workload, Therapy, ESR, Medical imaging

SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists' workload while enhancing cancer detection rates.

Key Points: 
  • This comprehensive study encompassed over 22,621 mammograms from 8,825 women over a decade.
  • Utilizing Lunit INSIGHT MMG, Lunit's AI-powered solution for breast cancer detection, the research aimed to assess its proficiency in early cancer detection within a breast cancer screening program.
  • This indicates a substantial step forward in improving the efficiency of breast cancer screening programs, potentially enabling broader screening coverage and reducing the burden on healthcare systems.
  • The study further revealed that the AI system identified 51.72% of interval cancers, and 50% of missed cancers.

i-Health, Inc. Urges U.S. Congressional Leaders to Prioritize the Funding of Natural & Non-Hormonal Solutions for Menopause in Women's Health Research

Retrieved on: 
Monday, April 8, 2024
Health, Attention, Congress, Government, Veteran, White, SVP, Executive order, Research, Menopause, History, Woman, Data collection, Hormone replacement therapy, Breast cancer, HRT, Hot, Amerifit Brands

i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.

Key Points: 
  • i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.
  • Research gaps are especially prevalent for health conditions associated with women's midlife and later years, including perimenopause and menopause."
  • The latest Executive Order from President Biden aims to close research gaps on women's health across their lifespans.
  • i-Health, Inc. the company behind Estroven®, the leading brand in natural, non-hormonal menopause relief‡, is committed to driving meaningful change for often overlooked health issues.

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Research, BCL9, MDSC, Survival, Patient, Wisdom, SVP, Neoplasm, The central science, Cancer, Macrophage, AP-1, IND, AACR, TAM, Phenotype, Therapy, Breast cancer, Poster, Cell, AP-1 transcription factor, TNBC, Metastasis, Vaccine

TARRYTOWN, N.Y., April 8, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of new data on its clinical and pipeline programs during three poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • We look forward to ST316 and ST101 continuing to advance through clinical development and moving our AP-1 program into IND-enabling studies."
  • Sapience scientists will present non-clinical immune-oncology results from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ.
  • In nonclinical studies, Sapience evaluated the ability of ST316 to enhance anti-tumor immune responses in combination with anti-PD-1 and anti-TIGIT therapies.
  • JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models.

USPS Honors Betty Ford

Retrieved on: 
Friday, April 5, 2024
Women's rights, Carnegie Hall, Equal Rights Amendment, Mastectomy, Newsroom, United, USPS, Republican Party, Disease, Betty Ford, Representative, Post, History, Female, Sale, Ford, Humour, Life, House, Collection, Betty Ford Center, Woman, Neck, News, Watergate scandal, Post office, White House Historical Association, Supreme court, Louisiana House of Representatives, The Postal Service, Breast cancer, Family, Hazelden Betty Ford Foundation, McReynolds, Divorce, Mail

RANCHO MIRAGE, Calif., April 5, 2024 /PRNewswire/ -- Today, the Postal Service issued a commemorative stamp celebrating the life of former First Lady Betty Ford on the campus of Eisenhower Health, adjacent to the Betty Ford Center in Rancho Mirage, CA. She was the wife of Gerald R. Ford, the 38th president, and widely admired for her support of women's rights and her candor about the serious health challenges she faced.

Key Points: 
  • RANCHO MIRAGE, Calif., April 5, 2024 /PRNewswire/ -- Today, the Postal Service issued a commemorative stamp celebrating the life of former First Lady Betty Ford on the campus of Eisenhower Health, adjacent to the Betty Ford Center in Rancho Mirage, CA.
  • Also attending were Susan Ford Bales, Betty Ford's daughter; Marty Massiello, CEO of Eisenhower Health; Dr. Joseph Lee, president and CEO of the Hazelden Betty Ford Foundation; and Tessa Voss, also of the foundation.
  • Betty Ford did that for both breast cancer and addiction — replacing shame and isolation with dignity, community and equitable care," Lee said.
  • In 1982, Ford and Leonard Firestone, a former ambassador and family friend, established the Betty Ford Center substance use disorder treatment center, which is now part of the nonprofit Hazelden Betty Ford Foundation.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.